We are powering the T-cell receptor (TCR) complex to provide more than just hope to cancer patients and a fundamental change for what it means to be diagnosed with solid tumors and hematologic malignancies.

Our TRuC-T cells are redefining the cell therapy landscape by harnessing the most powerful part of your immune system designed by evolution – the T-cell – directing it to specifically and sustainably attack your cancer.

  • Our Clinical Trials
  • Our Commitment

gavo-cel: Mesothelin-Positive Tumors

Stage of Development: Phase 1/2 Clinical Trial

Indications: Mesothelioma, Cholangiocarcinoma, Ovarian Cancer, Non-Small Cell Lung Cancer

Status: Active, Recruiting

Locations: National Cancer Institute; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Sarah Cannon Research Institute; University of Texas MD Anderson Cancer Center; University of California, San Francisco; Princess Margaret Cancer Centre

learn more at clinicaltrials.gov

Our Commitment

At TCR2, passion for patients is everything. Our Chief Executive Officer, Dr. Garry Menzel, wrote this letter on behalf of all of us to tell you how much you mean to us, and how we’re working every day to help.

We are at a point in scientific and clinical progress where curing cancer patients of their solid tumors has become a real possibility. At TCR2, we are driven by a passion to offer our patients that promise of tomorrow.

You can be reassured that we are motivated every single day by the power of discovery and the opportunity it brings to advance our noble cause of saving lives. We are all inspired to leave a meaningful legacy and I am proud to lead such a dedicated group of people who work tirelessly to innovate and provide new tools to fight cancer. Our long-term commitment is to bring our TRuC-T cells to patients all over the world and give you much more than a fighting chance against cancer.

– Dr. Garry Menzel, TCR² CEO